Trans-arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium

• Published in: Cancer imaging 2015-05, Vol.15 (1), p.7, Article 7
• Main Authors: Duan, Feng, Yu, Wei, Wang, Yan, Liu, Feng-yong, Song, Peng, Wang, Zhi-jun, Yan, Jie-yu, Yuan, Kai, Wang, Mao-qiang
• Format: Article
• Language: English
• Subjects: Adult; Aged; Analysis; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - radiotherapy; Carcinoma, Hepatocellular - therapy; Care and treatment; Chemoembolization, Therapeutic - methods; Combined Modality Therapy; Female; Heart Atria; Hepatocellular carcinoma; Humans; Liver Neoplasms - mortality; Liver Neoplasms - pathology; Liver Neoplasms - radiotherapy; Liver Neoplasms - therapy; Male; Middle Aged; Neoplasm Invasiveness; Patient outcomes; Radiation Dosage; Radiography, Interventional; Radiotherapy; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Safety and security measures; Therapeutic embolization; Thrombosis; Treatment outcome; Vena Cava, Inferior; Venous Thrombosis - pathology
• ISSN: 1470-7330; 1740-5025; 1470-7330
• DOI: 10.1186/s40644-015-0043-3

Hepatocellular carcinoma (HCC) with a tumor thrombus in the inferior vena cava (IVC) and right atrium (RA) rarely occurs and is usually associated with extremely poor prognosis, we carried out this study to evaluate the efficacy and safety of a combination of trans-arterial chemoembolization (TACE) and external beam radiation therapy (EBRT) in the treatment of HCC with a tumor thrombus in the IVC and RA. From September 2005 to September 2008, 11 cases of HCC with a tumor thrombus in the IVC and RA were treated with a combination of TACE and EBRT. Clinical adverse events, laboratory toxicity, and survival were retrospectively studied. Thirty-one interventional procedures were conducted and EBRT was performed 11 times. All treatments were successful and without significant complications. No severe adverse effects were observed. The median survival time of the 11 cases was 21.0 months. One patient was monitored for 97 months and no recurrence was observed. The combination of TACE and EBRT can be safely performed and may improve the prognosis of the HCC cases with a tumor thrombus in the IVC and RA.